Boyu Capital is a private equity firm that invests in consumer, retail, media and technology, healthcare, and financial services sectors.
Business Model: B2C
Revenue: $5M
Employees: 11-50
Address: 88 Queensway
City: Hong Kong
State: other
Zip:
Country: HK
Boyu Capital Consultancy Co. Ltd is a private equity firm specializing in investments in China. Boyu Capital Consultancy Co. Ltd was founded on September 28, 2010 and is based in Hong Kong with an additional office in Beijing, China.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
5/2013 | Berry Genomics | Series B | 14.7M |
5/2018 | China Chengxin Credit | Series A | 0 |
8/2021 | MediTrust Health | Series C | 0 |
10/2021 | WT Microtech Medical | Series E | 153M |
5/2018 | Brii Biosciences | Venture Round | 260M |
1/2019 | Yimidida | Series D | 266.1M |
3/2020 | Yuanfudao | Series G | 1B |
3/2020 | Pinduoduo | Post-IPO Equity | 1.1B |
6/2019 | Waterdrop | Series C | 144.6M |
4/2021 | Adcentrx Therapeutics | Series A | 50M |
9/2022 | Animoca Brands | Convertible Note | 110M |
9/2012 | Alibaba Group | Private Equity Round | 0 |
5/2018 | CStone Pharmaceuticals | Series B | 260M |
11/2021 | Positive Sequence Biology | Series A | 0 |
3/2020 | Yatsen Holding | Series D | 240M |
6/2022 | Frontera Therapeutics | Series B | 0 |
1/2021 | 4Paradigm | Series D | 0 |
1/2021 | Lalamove | Series F | 1.5B |
11/2021 | Edge Medical Robotics | Series C | 0 |
1/2019 | Antengene Corporation | Series B | 0 |
8/2021 | Abogen Biosciences | Series C | 0 |
6/2021 | ArriVent Biopharma | Series A | 81M |
2/2022 | ArriVent Biopharma | Series A | 69M |
12/2022 | ArriVent Biopharma | Series B | 0 |
6/2014 | COFCO | Post-IPO Equity | - |
12/2021 | Jinke | Post-IPO Equity | 478.6M |
11/2020 | D3 Bio | Series A | 200M |
2/2014 | LY.com | Series C | 82.3M |
8/2018 | KLOOK | Series D | 200M |
6/2022 | Evat Master | Series A | 0 |
7/2016 | CStone Pharmaceuticals | Series A | 150M |
8/2021 | MediTrust Health | Series C | 308.3M |
12/2021 | Recurrent.ai | Venture Round | 38M |
7/2020 | Antengene Corporation | Series C | 97M |
12/2019 | Kuaishou Technology | Series F | 3B |
2/2018 | Viela Bio | Series A | 0 |
11/2018 | NetEase Cloud Music | Series B | 600M |
7/2018 | Trax | Series D | 0 |
11/2021 | J&a;T Express | Private Equity Round | 0 |
11/2021 | Vision Medicals | Series D | 47M |
2/2017 | iQiyi | Series G | 1.5B |
8/2020 | Yuanfudao | Series G | 1.2B |
8/2021 | Zeekr | Series A | 500M |
7/2018 | MEGVII | Series D | - |
9/2018 | LianLian Pay | Venture Round | 146.6M |
7/2018 | Curon Biopharma | Series A | 150M |
9/2021 | XSKY Data Technology | Series E | 0 |
8/2021 | Pulse Medical Technology | Series C | 0 |
5/2022 | Shuaike Pet Food Products | Private Equity Round | 0 |
3/2022 | MoreSec | Series D | 0 |
6/2021 | RecBio | Series C | 156.3M |
1/2021 | KLOOK | Series E | 0 |
9/2017 | LifeMine Therapeutics | Series A | 0 |
9/2019 | Chengjia Apartment | Series A | 300M |
12/2020 | SciNeuro | Series A | 100M |
11/2017 | Berry Oncology | Series A | 121.2M |
4/2021 | J&a;T Express | Private Equity Round | 2B |
6/2022 | Frontera Therapeutics | Series B | 0 |
6/2022 | Evat Master | Series A | 0 |
5/2022 | Shuaike Pet Food Products | Private Equity Round | 0 |
3/2022 | MoreSec | Series D | 0 |
2/2022 | ArriVent Biopharma | Series A | 0 |
12/2021 | Recurrent.ai | Venture Round | 0 |
12/2021 | Jinke | Post-IPO Equity | 0 |
11/2021 | Vision Medicals | Series D | 0 |
11/2021 | J&a;T Express | Private Equity Round | 0 |
11/2021 | Positive Sequence Biology | Series A | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|